



ALMA MATER STUDIORUM UNIVERSITY OF BOLOGNA
Dipartimento di Chimica “G.Ciamician”

Biocatalysis: mechanism, synthesis, and applications. Part II

Daria Giacomini

daria.giacomini@unibo.it

Some selected milestones of industrially relevant biotransformation and biocatalytic processes



year	process
5000 BC	Vinegar production
800 BC	Casein hydrolysis with chymosin for cheese production
1670	“Orlean” process for the industrial bio-oxidation of ethanol to acetic acid
1680	Antoni van Leeuwenhoek first to see microorganisms with his microscope.
1897	E. Buchner discovers yeast enzymes converting sugar into alcohol
1934	Regioselective biooxidation of sorbite to sorbose for the Reichstein Vitamin C synthesis
1940	Sucrose inversion using an invertase
1950	Bioconversion of steroids
1970	Hydrolysis of penicillin to 6-aminopenicillanic acid
1973	First successful genetic engineering experiments
1974	Glucose to fructose isomerisation with immobilized glucose isomerase
1985	Enzymatic process for the production of acrylamide
1990	Hydrolysis by protease (trypsin) of porcine insuline to human insuline



Nomenclature

Bioconversion: Chemical conversion of a substance using biological methods (enzymes or whole cells, biocatalysis or biotransformation).


Biotransformation: Chemical conversion of a substance into a desired product with the aid of a living whole cell, containing the necessary enzyme(s).

Biocatalysis: Chemical conversion of a substance into a desired product with the aid of a free or immobilized enzyme.

Biosynthesis: De novo production of an entire molecule by a living organism. Unlike biotransformation which acts on a starting substance or educt, biosynthesis is not dependent on educts or starting substances, but only on nutrients.




Enzymes in Industry



Cumulative number of biotransformation processes that have been started on an industrial scale

Industrial sectors in which the products of industrial biotransformations are used (based on 134 processes).



Enzymes in Industry


Table 1

The application of enzyme technology in the chemical industry.


Industry sector*	Impact (estimate) ^{†‡}		
	Today	Near future	Distant future
Organics			
Food and feed additives	+++	+++	++
Fine chemicals	+	++	+++
Drugs (antibiotics, intermediates)	++	++	++
Plastic materials and synthetics	+	++	++
Soaps, cleaners, personal care products (lipases, proteases)	+	++	++
Inorganics	–	+	+
Miscellaneous chemical products (adhesives, pulp, textile and oil processing, waste water treatment)	+	+	++
Agricultural chemicals (herbicides, intermediates)	+	+	++

*As listed in Wittcoff and Reuben [36]. [†]Based on Tables 3, 4 and 5 and [10]. [‡]+++ , very high; ++ , high; + , moderate; – , low.


Enzymes in Industry



Enzyme types used in industrial biotransformations (based on 134 processes)



Enzymes in Industry



The type of compounds produced using biotransformation processes (based on 134 industrial processes).

Box 2. Green credentials of biocatalysis

Biocatalysis:

- operates in water (thus replacing organic solvents)
- has highly selective catalysis, including regio- and stereo-selectivity (thus reducing E-factors)
- operates in mild conditions, avoiding the need for protection (thus reducing E-factors)
- overcomes the use of some hazardous materials (resulting in improved LCA)
- uses renewable resources (resulting in improved LCA)
- can be modified, that is, the biocatalyst properties can be altered to suit the process (thus improving the ease of processing)
- is rarely endo- or exo-thermic (thus reducing energy requirements)
- provides a high yield as a result of selectivity and mild conditions (thus improving the efficiency of processing)
- is catalytic rather than stoichiometric (thus improving the ease of processing)

Enzymes in Industry

Pros:

- Selectivity
- Environmentally friendly





Cons:

- Substrate specificity
- Substrate unsolubility in aqueous solvents
- Cofactor dependency
- Expensive

Improvements:

- Engineered enzymes
- Use in organic solvents
- Cofactor recycle
- Immobilization
- Whole cells processes

Chiral Drugs



Chiral Drugs

The active enantiomer of a drug with the desired biological effect is called the **eutomer**


The other enantiomer is called the **distomer**.

Eudismic ratio is defined as the ratio of the biological activity of the eutomer to that of the distomer.

- the distomer may be inactive but....
- the distomer may possess harmful side effects e.g. thalidomide
- the distomer may be converted into the eutomer by the body e.g. ibuprofen.

Individual stereoisomers of a chiral drug should be tested as well as the racemate before a drug is marketed. This is because the presence of the distomer in a racemic drug can have important consequences on the biological activity.

Chiral Drugs



Current Opinion in Biotechnology

Synthesis of pure enantiomers




Fig. 1. Synthetic routes to pure enantiomers.

Biocatalysis in stereoselective synthesis


Resolutions:

kinetic resolution (KR)

dynamic kinetic resolution (DKR)



Desymmetrization

Asymmetric Synthesis





Source of chirality for the products of industrial biotransformations (based on 134 processes).

Enzymes and kinetic resolution




limited to 50% max yield

Enzymes and “Prils” synthesis




Enzymes and desymmetrization





Scheme 2. Lipase-catalysed acetylation of *meso-exo*-3,5-dihydroxymethylenetricyclo[5.2.1.0^{2,6}]decane, (**3**).

Enzymes in synthesis of antibiotics



Enzymes in synthesis of antibiotics




Ar = C₆H₅

Ampicillin



Ar = p-HOC₆H₄

Amoxycillin



Cefalexin

Cefadroxyl



X = RO, NH₂

Enzymes in synthesis of antibiotics




Fig. 7. Two routes to (R)-phenylglycine.

Enzymes in synthesis of antibiotics





Fig. 8. The hydantoin route to (*R*)-*p*-hydroxyphenylglycine.

Enzymes in synthesis of antibiotics




Scheme 1.

Penicillin G acylase mediated synthesis of the enantiopure (S)-3-amino-azetidin-2-one


G. Cainelli, D. Giacomini, P. Galletti, M. DaCol

Tetrahedron: Asymmetry, Vol. 8, No. 19, pp. 3231-3235, 1997

Enzymes in synthesis of anticancer drugs



Biocatalysis in Atorvastatin synthesis



inhibitors of HMC-CoA







Fig. 1

Biocatalysis in Atorvastatin synthesis




1


Atorvastatin



or



Dehydrogenase approach



Isolated Enzyme:

Alcohol Dehydrogenase
from *Lactobacillus Brevis*


isolated yield 75%
ee > 99.5 %

Co-factor recycling:








Coupled substrate process
with one single enzyme
(ADH) and isopropanol as
co-substrate

Whole cell:




Alcohol Dehydrogenase
from *Lactobacillus Kefir*





Dehydrogenase approach



Aldolase approach



Nitrilase approach



Desymmetrization step

wild type


0.2 M substrate: Y = 98% ee = 95%

3 M substrate: Y = 89% ee = 87%




mutant

3 M substrate Y = 96% ee = 98.5%


Lipase approach





Lipase approach



Chemical *versus* chemo-enzymatic syntheses: a comparison




Chemical *versus* chemo-enzymatic syntheses: a comparison




Chemical *versus* chemo-enzymatic syntheses: a comparison

chemical



Current Opinion in Chemical Biology

chemo-enzymatic



Enzymes in Organic solvents

Maggiore stabilità termica degli enzimi in solvente organico (thermal unfolding, thermal deamidation)

Aumentata solubilità dei substrati

Separazione piu' facile dei prodotti di reazione

Multi-phase reactors


Spostamento dell'equilibrio delle reazioni

Selettività diversa rispetto al solvente acquoso
"medium engineering"

Lipasi

Deidrogenasi


Membrane Reactor



Solvent effects on enantioselectivity


Properties and Synthetic Applications of Enzymes in Organic Solvents

Giacomo Carrea* and Sergio Riva*




Enzyme selectivity in organic solvents can differ from that in water and can change, or even reverse, from one solvent to another.


Angew. Chem. Int. Ed. 2000, 39, 2226–2254



la presenza di molecole di solvente nel sito attivo dell'enzima




modifica del sito attivo da parte del solvente




il substrato si desolvata prima di entrare nel sito attivo

il substrato entra all'interno dell'enzima come cluster soluto solvente




Engineered Phenylalanine Dehydrogenase (PheDH-N145A)




G.Cainelli, P.C.Engel, P.Galletti, D.Giacomini, A.Gualandi, F.Paradisi, *Org. Biomol. Chem.*, 2005, 3, 4316
Patent WO 2006015885 A1 20060216 CAN 144:252784 2006.

Horse Liver Alcohol Dehydrogenase (HLADH)




D. Giacomini, P. Galletti, A. Quintavalla, a G. Gucciardob, F. Paradisi *Chem Commun*, 2007, 4038
Patent Pending, PCT/EP2007/063844, RM2006A000686, University of Bologna

Engineered Phenylalanine Dehydrogenase in Organic Solvents



PheDH-N145A on Celite



NH_4Cl



NADH

NAD⁺

Saccharomyces Cerevisiae



Enzyme

Engineered Phenyl
Alanine Dehydrogenase
(PheDH-N145A)
immobilised on
Celite®521

Co-factor recycling

coupled enzyme
process with
Saccharomyces
Cerevisiae and ethanol
as co-substrate

Reaction Medium


Homogeneous system

aqueous buffer (TRIS pH 8.5) with
miscible organic solvents

Biphasic system


aqueous buffer (TRIS pH 8.5) and
immiscible organic solvents

Homogeneous medium: buffer and THF, acetone, or methanol





PheDH-N145A on Celite

NH_4Cl





NADH NAD⁺

Saccharomyces Cerevisiae




Biphasic medium : buffer with *n*hexane, toluene, Et₂O, *t*BuOMe, or CH₂Cl₂




PheDH-N145A on Celite


NH₄Cl



NADH NAD⁺




Saccharomyces Cerevisiae



Alcohol Dehydrogenases




Yeast Alcohol
Dehydrogenases




Horse Liver Alcohol Dehydrogenases

Horse Liver Alcohol Dehydrogenase in Organic Solvents



Enzyme

Horse Liver Alcohol
Dehydrogenase (HLADH)



Co-factor recycling

Coupled substrate process with one
single enzyme (HLADH) and ethanol
as co-substrate

Reaction Medium



Homogeneous system

aqueous buffer (phosphate pH 7.5)
with miscible organic solvents

Biphasic system

aqueous buffer (phosphate pH 7.5)
and immiscible organic solvents

Enantioselective enzymatic reduction: 2-Phenylpropanal





Chiralcel OF, 0.5
mL/min,
hexane/iPrOH
93/7


D. Giacomini, P. Galletti, A. Quintavalla, G. Gucciardo, F. Paradisi *Chem Commun*, 2007, 4038

D. Giacomini, P. Galletti, F. Paradisi *Innovation Technology* 2008, 78.


Enantioselective Bioreduction with Stereo-inversion



Dynamic Kinetic Resolution process via keto-enol tautomerism




Dynamic Kinetic Resolution: Beyond the Kinetic Resolution



Kinetic Resolution


max.theoretical yield 50%



Dynamic Kinetic Resolution

max.theoretical yield 100%


Dynamic Kinetic Resolution with organic co-solvents




entry	co-solvent (%)	NADH recycle	time (h)	HLADH (mg/ml)	yield %	S%	R%
1	CH ₃ CN (10)	no	5	0.01	71.9	89	11
2*	CH ₃ CN (16)	yes	96	0.09	90.3	94	6
3	THF (10)	no	5	0.01	54.7	96	4
4	THF (10)	yes	5	0.01	54.1	95	5
5	<i>n</i> hexane (90)	no	5	0.2	69.9	74	26
6	<i>n</i> hexane (95)	no	5	0.2	80.3	64	36
7	<i>n</i> hexane (95)	yes	5	0.2	68.0	72	28
8	<i>n</i> hexane (99)	yes	5	0.2	54.6	90	10

* 1 mmol scale


Profens: a family of (S)-enantiomers dedicated to inflammation




Ibuprofen




Naproxen



Flurbiprofen




Ketoprofen



Phenoprofen

Profen-aldehydes synthesis



References

R. A. Sheldon *Chirotechnology* Marcel Dekker, 1993

K. Faber *Biotransformations in organic chemistry : a textbook* Springer, 2000

A.S.Bommarius, B.R.Riebel *Biocatalysis* Wiley-VCH , 2004

R. Patel *Stereoselective Biocatalysis*, Marcel Dekker, Inc., 2000.


A.J.J. Straathof, S. Panke, A.Schmid The production of fine chemicals by biotransformations
Current Opinion in Biotechnology 2002, 13: 548–556

R. Kazlauskas *Integrating Biocatalysis into organic synthesis*
Tetrahedron: Asymmetry 2004, 2727

R.A.Sheldon, F. van Rantwijk *Biocatalysis for sustainable Organic Synthesis*
Aus. J. Chem. 2004, 57,281-289.

Patel, Coordination Chemistry Reviews 252 (2008) 659–701

Enzymes in Industry



TRENDS in Biotechnology


Cofactor-dependent enzyme catalysis in functionalized ionic solvents†

Adam J. Walker^{a,b} and Neil C. Bruce^{a,b}

^a CNAP, Department of Biology (Area 8), University of York, PO Box 373, York, UK YO10 5YW.


E-mail: aw41@york.ac.uk; Fax: +(44)1904 328786; Tel: +(44)1904 328777

^b Institute of Biotechnology, University of Cambridge, Tennis Court Road, Cambridge, UK CB2 1QT



Chem. Commun., 2004, 2570 - 2571

Fluorous phase



Scheme 1. Lipase-catalyzed kinetic resolution of racemic 1-phenylethanol (1) and desymmetrization of meso-2-cyclopentene-1,4-diol (4).

Table 1: Kinetic resolution of 1-phenylethanol (1) catalyzed by Novozym 435.

Solvent	t ^[a] [h]	Conv. [%]	ee (S)-1 [%]	ee (R)-3 [%]	Initial rates ^[b] [nmol min ⁻¹ mg ⁻¹]			
					a _w < 0.01	a _w ≈ 0.43	a _w ≈ 0.58	a _w ≈ 0.75
R-32	5	50	> 99	> 99	n.d. ^[c]	n.d.	n.d.	n.d.
R-227ea	3.5	49	96	> 99	n.d.	n.d.	n.d.	n.d.
R-134a	4	49	96	> 99	325	387	407	358
hexane	8	46	85	> 99	227	241	260	228
MTBE	35	49	96	> 99	51	64	68	60

[a] The time point when no further reaction was evident (that is, the rate of the reaction was approaching zero). [b] Initial rates are given in units of nmol of product 3 per minute per mg of enzyme and were determined from the slope of the time-course measurements between 0 and 5% conversion for an approximate water activity (a_w). [c] n.d. = not determined.

Angew. Chem. Int. Ed. 2004, 43, 5519–5523